Otros idiomas MediciNova, Inc.

Acciones

MNOV

US58468P2065

Mercado cerrado - Nasdaq Otros sitios de cotización 22:30:00 01/05/2024			Varia. Cinco días.	Varia. 1 de enero.
1,29 ^USD	0,00 %		-4,80 %	-14,00 %

27/03	MediciNova, Inc. Recibe una Notificación de Permiso para una nueva patente que cubre el MN-166 (ibudilast) para el tratamiento de la lesión macular en Japón	CI
12/03	Medicinova anuncia nuevos datos y resultados del Mn-166 (Ibudilast) en la lesión pulmonar aguda inducida por gas cloro presentados en la 63ª Reunión Anual de la Sociedad de Toxicología	CI

Otros idiomas

Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!

Inscripción 100% Gratuita

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting	03/04
MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)	03/04
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	27/03
MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan	27/03
MediciNova, Inc. Receives a Notice of Allowance for a New Patent Covering MN-166 for the Treatment of Macular Injury in Japan	27/03
MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society	21/03
MediciNova : Corporate Presentation – March 15, 2024	15/03
MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology	12/03
Medicinova Announces New Data and Results of Mn-166 in Chlorine Gas-Induced Acute Lung Injury Presented At the 63Rd Annual Meeting of the Society of Toxicology	12/03
MNOV: Capital Efficient Model and Large Late-Stage Pipeline Makes MediciNova Stand Out Among Peers – February 29, 2024	29/02
MediciNova, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	15/02
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China	18/01
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China	17/01
MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 for the Treatment of Macular Injury in China	17/01
Top Premarket Gainers	12/01
MediciNova Announces Abstract Regarding MN-166 in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	22/12
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	22/12
MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	22/12
MediciNova, Inc. Announces Abstract Regarding MN-166 in Chlorine Gas-Induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology	22/12
MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 for the Treatment of Progressive MS in Europe	07/12

No hay resultados para esta búsqueda

Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Otros idiomas MediciNova, Inc.

Acciones

MNOV

US58468P2065

Otros idiomas

Filtros